Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC

NCT07341100 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Epithelial Cancer

Interventions

DRUG: SKB264
DRUG: Clarithromycin

Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.